Literature DB >> 25149917

How good is "evidence" from clinical studies of drug effects and why might such evidence fail in the prediction of the clinical utility of drugs?

Huseyin Naci1, John P A Ioannidis.   

Abstract

Promising evidence from clinical studies of drug effects does not always translate to improvements in patient outcomes. In this review, we discuss why early evidence is often ill suited to the task of predicting the clinical utility of drugs. The current gap between initially described drug effects and their subsequent clinical utility results from deficits in the design, conduct, analysis, reporting, and synthesis of clinical studies-often creating conditions that generate favorable, but ultimately incorrect, conclusions regarding drug effects. There are potential solutions that could improve the relevance of clinical evidence in predicting the real-world effectiveness of drugs. What is needed is a new emphasis on clinical utility, with nonconflicted entities playing a greater role in the generation, synthesis, and interpretation of clinical evidence. Clinical studies should adopt strong design features, reflect clinical practice, and evaluate outcomes and comparisons that are meaningful to patients. Transformative changes to the research agenda may generate more meaningful and accurate evidence on drug effects to guide clinical decision making.

Entities:  

Keywords:  bias; clinical trials; drug therapy; precision medicine; prediction in pharmacology; treatment effectiveness

Mesh:

Year:  2014        PMID: 25149917     DOI: 10.1146/annurev-pharmtox-010814-124614

Source DB:  PubMed          Journal:  Annu Rev Pharmacol Toxicol        ISSN: 0362-1642            Impact factor:   13.820


  22 in total

1.  An increasing problem in publication ethics: Publication bias and editors' role in avoiding it.

Authors:  Perihan Elif Ekmekci
Journal:  Med Health Care Philos       Date:  2017-06

2.  Timing and Characteristics of Cumulative Evidence Available on Novel Therapeutic Agents Receiving Food and Drug Administration Accelerated Approval.

Authors:  Huseyin Naci; Olivier J Wouters; Radhika Gupta; John P A Ioannidis
Journal:  Milbank Q       Date:  2017-06       Impact factor: 4.911

3.  A Pharmacovigilance Signaling System Based on FDA Regulatory Action and Post-Marketing Adverse Event Reports.

Authors:  Keith B Hoffman; Mo Dimbil; Nicholas P Tatonetti; Robert F Kyle
Journal:  Drug Saf       Date:  2016-06       Impact factor: 5.606

4.  Most psychotherapies do not really work, but those that might work should be assessed in biased studies.

Authors:  J P A Ioannidis
Journal:  Epidemiol Psychiatr Sci       Date:  2016-03-08       Impact factor: 6.892

5.  TREAP: A New Topological Approach to Drug Target Inference.

Authors:  Muying Wang; Lauren L Luciani; Heeju Noh; Ericka Mochan; Jason E Shoemaker
Journal:  Biophys J       Date:  2020-10-29       Impact factor: 4.033

6.  MAIN ETHICAL BREACHES IN MULTICENTER CLINICAL TRIALS REGULATIONS OF TURKEY.

Authors:  P Elif Ekmekci
Journal:  Med Law       Date:  2016

Review 7.  Modeling neurodevelopmental cognitive deficits in tasks with cross-species translational validity.

Authors:  Z A Cope; S B Powell; J W Young
Journal:  Genes Brain Behav       Date:  2016-01       Impact factor: 3.449

8.  The druggable genome and support for target identification and validation in drug development.

Authors:  Chris Finan; Anna Gaulton; Felix A Kruger; R Thomas Lumbers; Tina Shah; Jorgen Engmann; Luana Galver; Ryan Kelley; Anneli Karlsson; Rita Santos; John P Overington; Aroon D Hingorani; Juan P Casas
Journal:  Sci Transl Med       Date:  2017-03-29       Impact factor: 17.956

9.  Evaluation of Drug Trials in High-, Middle-, and Low-Income Countries and Local Commercial Availability of Newly Approved Drugs.

Authors:  Jennifer E Miller; Michelle M Mello; Joshua D Wallach; Emily M Gudbranson; Blake Bohlig; Joseph S Ross; Cary P Gross; Peter B Bach
Journal:  JAMA Netw Open       Date:  2021-05-03

10.  Pharmacologic therapies for neuropathic pain: an assessment of reporting biases in randomized controlled trials.

Authors:  Stefani M Schwartz; Awinita Barpujari; Nanna Brix Finnerup; Srinivasa N Raja
Journal:  Pain       Date:  2022-04-01       Impact factor: 7.926

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.